CCL three-lens brief
Evidence-based stock research on CCL. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA below 200-day MA (death-cross regime); price below both. · Debt-to-equity of 202% — balance-sheet-heavy.
- 50-day MA below 200-day MA (death-cross regime); price below both.
- Analyst mean target $35.63 — 33% above current (25 analysts).
- Debt-to-equity of 202% — balance-sheet-heavy.
CCL closed at $26.88 (+0.58%) as of 2026-07-10. Market cap: $36.81B. P/E (trailing) 12.1. Price is below the 50-day MA and below the 200-day MA. Positives: analyst mean target $35.63 — 33% above current (25 analysts).. Concerns: 50-day MA below 200-day MA (death-cross regime); price below both.; debt-to-equity of 202% — balance-sheet-heavy.. Last quarter: Revenue $6.66B, net income $537.00M, free cash flow $1.90B.
Why three lenses on CCL, not one.
A single reasoning model has blind spots it doesn’t know about. We examine CCLacross Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/CCL" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath CCL brief"></iframe>